Ionis Pharmaceuticals (IONS) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 4, 2026, and will be held virtually, allowing shareholders to vote and submit questions online.

• Key agenda items include director elections, advisory vote on executive compensation, amendments to equity and stock purchase plans, and auditor ratification.

• Shareholders are encouraged to vote electronically to reduce environmental impact and costs.

• The company highlights its transition to a fully integrated commercial-stage biotech, recent product launches, and strong financial discipline.

Voting matters and shareholder proposals

• Election of two directors, Spencer R. Berthelsen and Joan E. Herman, for three-year terms.

• Advisory (nonbinding) vote on executive compensation (“say on pay”).

• Approval of amendments to the 2011 Equity Incentive Plan (increase by 9.5M shares) and 2000 Employee Stock Purchase Plan (increase by 750K shares, remove termination date).

• Ratification of Ernst & Young LLP as independent auditors for 2026.

• Shareholder proposals for the next annual meeting must be submitted by December 24, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board is divided into three classes, with annual elections for expiring terms; current board has ten members.

• Board committees include Audit, Compensation, Nominating/Governance, Medical and Science, Finance, and Compliance.

• Majority of directors are independent per Nasdaq and SEC standards; CEO is the only non-independent director.

• Board diversity includes three female and two ethnically diverse directors.

• Corporate governance guidelines, code of ethics, anti-hedging/pledging policies, and stockholder communication processes are in place.